Resuscitation
Volume 81, Issue 4 , Pages 481-487 , April 2010

Nitroglycerin attenuates vasoconstriction of HBOC-201 during hemorrhagic shock resuscitation

  • Laurence M. Katz

      Affiliations

    • Department of Emergency Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, United States
    • Corresponding Author InformationCorresponding author at: Campus Box 7594, Physician Office Building 1st Floor Room p1114, 170 Manning Drive, Chapel Hill, NC 27599, United States. Tel.: +1 919 843 1966; fax: +1 919 966 3049.
    • ,
  • James E. Manning

      Affiliations

    • Department of Emergency Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, United States
    • ,
  • Shane McCurdy

      Affiliations

    • Department of Emergency Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, United States
    • ,
  • Charles Sproule

      Affiliations

    • Department of Emergency Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, United States
    • ,
  • Gerald McGwin Jr.

      Affiliations

    • Department of Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, United States
    • ,
  • Paula Moon-Massat

      Affiliations

    • Combat Casualty Directorate, Naval Medical Research Center, Silver Springs, MD, United States
    • ,
  • Charles B. Cairns

      Affiliations

    • Department of Emergency Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, United States
    • ,
  • Daniel Freilich

      Affiliations

    • Combat Casualty Directorate, Naval Medical Research Center, Silver Springs, MD, United States
    • Infectious Diseases, National Naval Medical Center, Silver Springs, MD, United States
    • Medicine and Surgery Departments, Uniformed Services University of the Health Sciences, Bethesda, MD, United States

Received 1 September 2009 ,Revised 24 November 2009 ,Accepted 17 December 2009.

References 

  1. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA. 2008;299:2304–2312
  2. Food and Drug Administration Blood Product Advisory Committee 88th Meeting, December 14, 2006, http://www.fda.gov/OHRMS/DOCKETS/ac/cber2006.html#BloodProducts; 2006 [accessed 25.09.09].
  3. Minneci PC, Deans KJ, Shiva S, et al. Nitrite reductase activity of hemoglobin as a systemic nitric oxide generator mechanism to detoxify plasma hemoglobin produced during hemolysis. Am J Physiol Heart Circ Physiol. 2008;295:H743–H754
  4. Kavdia M, Tsoukias NM, Popel AS. Model of nitric oxide diffusion in an arteriole: impact of hemoglobin-based blood substitutes. Am J Physiol. 2002;282:H2245–H2253
  5. Huellner MW, Schrepfer S, Weyand M, et al. Inhibition of aldehyde dehydrogenase type 2 attenuates vasodilatory action of nitroglycerin in human veins. FASEB J. 2008;22:2561–2568
  6. Marsh N, Marsh A. A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clin Exp Pharmacol Physiol. 2000;27:313–319
  7. Rude RE, Muller JE, Braunwald E. Efforts to limit the size of myocardial infarcts. Ann Intern Med. 1981;95:736–761
  8. Pearce LB, Gawryl MS. The pharmacology of tissue oxygenation by biopure's hemoglobin-based oxygen carrier Hemopure (HBOC-201). Adv Exp Med Biol. 2003;530:261–270
  9. Standl T. Haemoglobin-based erythrocyte transfusion substitutes. Expert Opin Biol Ther. 2001;1:831–843
  10. Pearce LGM. Overview of preclinical and clinical efficacy of Biopure's HBOCs. vol. 2. Basel, Switzerland: Krager Landes Systems; 1998;
  11. McNiff EF, Yacobi A, Young-Chang FM, Golden LH, Goldfarb A, Fung HL. Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects. J Pharm Sci. 1981;70:1054–1058
  12. Katz LM, Manning JE, McCurdy S, et al. HBOC-201 improves survival in a swine model of hemorrhagic shock and liver injury. Resuscitation. 2002;54:77–87
  13. Manning JE, Katz LM, Brownstein MR, Pearce LB, Gawryl MS, Baker CC. Bovine hemoglobin-based oxygen carrier (HBOC-201) for resuscitation of uncontrolled, exsanguinating liver injury in swine. Carolina Resuscitation Research Group. Shock. 2000;13:152–159
  14. Shearburn EW, Craig WD, Maitland CL, Howard PL, McCoy S, Drucker WR. Hemodynamic and metabolic alterations in peripheral tissue during hemorrhagic shock. Am Surg. 1975;41:696–703
  15. Ali SZ, Bracht H, Krejci V, et al. The immediate and sustained effects of volume challenge on regional blood flows in pigs. Anesth Analg. 2008;106:595–600
  16. Waxman K, Tremper KK, Mason GR. Blood and plasma substitutes—plasma expansion and oxygen transport properties. West J Med. 1985;143:202–206
  17. Salmon JB, Mythen MG. Pharmacology and physiology of colloids. Blood Rev. 1993;7:114–120
  18. Doherty DH, Doyle MP, Curry SR, et al. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat Biotechnol. 1998;16:672–676
  19. Patel RP. Biochemical aspects of the reaction of hemoglobin and NO: implications for Hb-based blood substitutes. Free Radic Biol Med. 2000;28:1518–1525
  20. Thompson A, McGarry AE, Valeri CR, Lieberthal W. Stroma-free hemoglobin increases blood pressure and GFR in the hypotensive rat: role of nitric oxide. J Appl Physiol. 1994;77:2348–2354
  21. Doyle MP, Hoekstra JW. Oxidation of nitrogen oxides by bound dioxygen in hemoproteins. J Inorg Biochem. 1981;14:351–358
  22. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109–142
  23. Yu B, Raher MJ, Volpato GP, Bloch KD, Ichinose F, Zapol WM. Inhaled nitric oxide enables artificial blood transfusion without hypertension. Circulation. 2008;117:1982–1990
  24. Bilello K, Schultz S, Powell C, Jaffin J, Cole F, Malcolm D. Diaspirin crosslinked hemoglobin (DCLHb): control of pressor effect with anti-hypertensive agents. Artif Cells Blood Substit Immobil Biotechnol. 1994;22:819–825
  25. Rioux F, Drapeau G, Marceau F. Recombinant human hemoglobin (rHb1.1) selectively inhibits vasorelaxation elicited by nitric oxide donors in rabbit isolated aortic rings. J Cardiovasc Pharmacol. 1995;25:587–594
  26. Erhart SM, Cole DJ, Patel PM, Drummond JC, Burhop KE. Effect of alpha–alpha diaspirin crosslinked hemoglobin (DCLHb) on the potency of sodium nitroprusside and nitroglycerine to decrease blood pressure in rats: a dose–response study. Artif Cells Blood Substit Immobil Biotechnol. 2000;28:385–396
  27. Troncy E, Francoeur M, Salazkin I, et al. Extra-pulmonary effects of inhaled nitric oxide in swine with and without phenylephrine. Br J Anaesth. 1997;79:631–640
  28. Quezado ZM, Natanson C, Karzai W, et al. Cardiopulmonary effects of inhaled nitric oxide in normal dogs and during E. coli pneumonia and sepsis. J Appl Physiol. 1998;84:107–115
  29. Groves PH, Lewis MJ, Cheadle HA, Penny WJ. SIN-1 reduces platelet adhesion and platelet thrombus formation in a porcine model of balloon angioplasty. Circulation. 1993;87:590–597
  30. Zhang J, Somers M, Cobb FR. Heterogeneous effects of nitroglycerin on the conductance and resistance coronary arterial vasculature. Am J Physiol. 1993;264:H1960–H1968
  31. Feelisch M, Noack E. Nitric oxide (NO) formation from nitrovasodilators occurs independently of hemoglobin or non-heme iron. Eur J Pharmacol. 1987;142:465–469
  32. Wang P, Ba ZF, Chaudry IH. Endothelial cell dysfunction occurs very early following trauma-hemorrhage and persists despite fluid resuscitation. Am J Physiol. 1993;265:H973–H979
  33. Linberg R, Conover CD, Shum KL, Shorr RG. Hemoglobin based oxygen carriers: how much methemoglobin is too much?. Artif Cells Blood Substit Immobil Biotechnol. 1998;26:133–148
  34. Brower V. Fast tracking drugs to patients. Drug approval agencies are frequently criticised for either being too slow or too fast. EMBO Rep. 2002;3:14–16
  35. Knudson MM, Lee S, Erickson V, Morabito D, Derugin N, Manley GT. Tissue oxygen monitoring during hemorrhagic shock and resuscitation: a comparison of lactated Ringer's solution, hypertonic saline dextran, and HBOC-201. J Trauma. 2003;54:242–252
  36. Kelm M, Feelisch M, Deussen A, Strauer BE, Schrader J. Release of endothelium derived nitric oxide in relation to pressure and flow. Cardiovasc Res. 1991;25:831–836
  37. Proctor KG. Blood substitutes and experimental models of trauma. J Trauma. 2003;54:S106–S109
  38. Moore FA, McKinley BA, Moore EE. The next generation in shock resuscitation. Lancet. 2004;363:1988–1996
  39. Jost S, Reil G, Knop I, et al. Coronary vasodilation with nitrocompounds—is there a maximum?. Z Kardiol. 1989;78:38–40
  40. Noonan PK, Williams RL, Benet LZ. Dose dependent pharmacokinetics of nitroglycerin after multiple intravenous infusions in healthy volunteers. J Pharmacokinet Biopharm. 1985;13:143–157

☆ A Spanish translated version of the abstract of this article appears as Appendix in the final online version at doi:10.1016/j.resuscitation.2009.12.015.

☆☆ The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government.

PII: S0300-9572(09)00669-8

doi: 10.1016/j.resuscitation.2009.12.015

Resuscitation
Volume 81, Issue 4 , Pages 481-487 , April 2010

Article Tools

* Image Usage & Resolution